QNRX News and Press, Quoin Pharmaceuticals Ltd. From 11/08/23

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Quoin Pharmaceuticals Ltd. (QNRX) is expected to report $-2.4 for Q3 2023

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quar...

Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company&#...

Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints No Safety Concerns Observed in the Study to Date ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company&#x...

2023-08-07 01:24:01 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Results Earnings Conference Call August 3, 2023, 08:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference...

2023-08-02 17:42:42 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q2 GAAP EPS of -$2.13. Quoin expects its cash runway will extend well into 2H 2024. Quoin had approximately $15.4 million in cash, cash equivalents and marketable securities as of June 30, 202...

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study Subject’s skin was assessed to be fully clear by Investigator at QRX003 treatment areas Subject also demonstrated key improvements across all other cl...

ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second qua...

2023-07-24 08:34:47 ET Kodiak Sciences ( KOD ) -53% announces topline results from its phase 3 Studies of tarcocimab tedromer in Neovascular age-related macular degeneration and diabetic macular edema. Contango Ore ( CTGO ) -25% . 22nd Century Group ( XXII ...